Peak Bio, Inc. Common Stock
PKBO
PKBO was delisted on the 9th of January, 2023.
43 hedge funds and large institutions have $43.3M invested in Peak Bio, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
2% more funds holding
Funds holding: 42 → 43 (+1)
1% less capital invested
Capital invested by funds: $43.7M → $43.3M (-$382K)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$580K |
| 2 |
MTCM
Mint Tower Capital Management
Amsterdam,
Netherlands
|
+$558K |
| 3 |
MSU
Mizuho Securities USA
New York
|
+$496K |
| 4 |
WRBC
W.R. Berkley Corp
Greenwich,
Connecticut
|
+$300K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$254K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Meteora Capital
Boca Raton,
Florida
|
-$1.98M |
| 2 |
SFM
Spartan Fund Management
Toronto, Ontario,
Canada
|
-$599K |
| 3 |
KIM
Karpus Investment Management
Pittsford,
New York
|
-$496K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$314K |
| 5 |
BCM
Basso Capital Management
Stamford,
Connecticut
|
-$248K |
PKBO Hedge Fund Activity: Q3 2022 in Review
43 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Peak Bio, Inc. Common Stock (PKBO) for Q3 2022, worth a combined $43.3M — down 0.87% from $43.7M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PKBO positions and 3 closed out — a net gain of 1 holder — while 7 added to existing stakes and 8 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $580K. The largest seller was Meteora Capital, exiting entirely with an estimated $1.98M sold.
- 43 institutional investors held Peak Bio, Inc. Common Stock (PKBO) as of Q3 2022, up from 42 in Q2 2022.
- Funds reported $43.3M of Peak Bio, Inc. Common Stock stock for Q3 2022, down 0.87% quarter-over-quarter.
- 4 funds opened new Peak Bio, Inc. Common Stock positions in Q3 2022 and 3 closed out, a net change of +1 holder.
- The largest Peak Bio, Inc. Common Stock buyer in Q3 2022 was Janus Henderson Group, an estimated $580K added.
- The largest Peak Bio, Inc. Common Stock seller in Q3 2022 was Meteora Capital, an estimated $1.98M sold.
Based on aggregated 13F filings for Q3 2022.